Ethical questions in human clinical psychopharmacology: Should the focus be on placebo administration?

G. D. Kotzalidis, I. Pacchiarotti, G. Manfredi, V. Savoja, C. Torrent, L. Mazzarini, C. Tatarelli, B. Amann, S. Di Marzo, J. Sánchez-Moreno, G. Sani, P. Girardi, F. Colom, E. Vieta

Research output: Contribution to journalArticle

Abstract

Of all ethical issues in clinical trial designs, only placebo use is dealt with acrimony and unwarranted, rhetoric emphasis. Many misconceptions are biased and may hamper research in the mechanisms of healing and recovery if placebo is banned from clinical trials, as some influential ethicists propose. Current treatments in psychiatry are by no means optimal and may vary in their effect across studies, rendering difficult to find the best available therapeutic method with which to compare new drugs. Because drugs possess specific mechanisms, it is not possible to compare drugs with different mechanisms as to their relevance in the pathophysiology of a given disorder. Placebo acts through non-specific mechanisms and is the ideal control for any disorder whose pathophysiology is relatively unknown and its treatment is still suboptimal. Sticking to short-term patient benefit in a trial reflects an individualistically oriented thinking in contemporary ethics and is likely to limit further research and efforts to better understand the mechanisms of disease and drug action, but also those related to general body reactance and self-healing, which are enhanced by placebo administration. Because in history ethics are swinging between two opposed views, it is possible that in the near future, the balance will move towards communitarianism, which is more likely to better serve long-term patient needs. Ethicists should also consider some other aspects of human experimentation, such as the consistency of research lines and the trend to substitute older drugs with their metabolites or enantiomers.

Original languageEnglish
Pages (from-to)590-597
Number of pages8
JournalJournal of Psychopharmacology
Volume22
Issue number6
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Psychopharmacology
Placebos
Ethics
Ethicists
Pharmaceutical Preparations
Human Experimentation
Research
Clinical Trials
Social Responsibility
Psychiatry
Therapeutics
History

Keywords

  • Ethics
  • Placebo
  • Randomised clinical trials

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Kotzalidis, G. D., Pacchiarotti, I., Manfredi, G., Savoja, V., Torrent, C., Mazzarini, L., ... Vieta, E. (2008). Ethical questions in human clinical psychopharmacology: Should the focus be on placebo administration? Journal of Psychopharmacology, 22(6), 590-597. https://doi.org/10.1177/0269881108089576

Ethical questions in human clinical psychopharmacology : Should the focus be on placebo administration? / Kotzalidis, G. D.; Pacchiarotti, I.; Manfredi, G.; Savoja, V.; Torrent, C.; Mazzarini, L.; Tatarelli, C.; Amann, B.; Di Marzo, S.; Sánchez-Moreno, J.; Sani, G.; Girardi, P.; Colom, F.; Vieta, E.

In: Journal of Psychopharmacology, Vol. 22, No. 6, 08.2008, p. 590-597.

Research output: Contribution to journalArticle

Kotzalidis, GD, Pacchiarotti, I, Manfredi, G, Savoja, V, Torrent, C, Mazzarini, L, Tatarelli, C, Amann, B, Di Marzo, S, Sánchez-Moreno, J, Sani, G, Girardi, P, Colom, F & Vieta, E 2008, 'Ethical questions in human clinical psychopharmacology: Should the focus be on placebo administration?', Journal of Psychopharmacology, vol. 22, no. 6, pp. 590-597. https://doi.org/10.1177/0269881108089576
Kotzalidis, G. D. ; Pacchiarotti, I. ; Manfredi, G. ; Savoja, V. ; Torrent, C. ; Mazzarini, L. ; Tatarelli, C. ; Amann, B. ; Di Marzo, S. ; Sánchez-Moreno, J. ; Sani, G. ; Girardi, P. ; Colom, F. ; Vieta, E. / Ethical questions in human clinical psychopharmacology : Should the focus be on placebo administration?. In: Journal of Psychopharmacology. 2008 ; Vol. 22, No. 6. pp. 590-597.
@article{244a7c7ee3c742f5b078580e7a73d369,
title = "Ethical questions in human clinical psychopharmacology: Should the focus be on placebo administration?",
abstract = "Of all ethical issues in clinical trial designs, only placebo use is dealt with acrimony and unwarranted, rhetoric emphasis. Many misconceptions are biased and may hamper research in the mechanisms of healing and recovery if placebo is banned from clinical trials, as some influential ethicists propose. Current treatments in psychiatry are by no means optimal and may vary in their effect across studies, rendering difficult to find the best available therapeutic method with which to compare new drugs. Because drugs possess specific mechanisms, it is not possible to compare drugs with different mechanisms as to their relevance in the pathophysiology of a given disorder. Placebo acts through non-specific mechanisms and is the ideal control for any disorder whose pathophysiology is relatively unknown and its treatment is still suboptimal. Sticking to short-term patient benefit in a trial reflects an individualistically oriented thinking in contemporary ethics and is likely to limit further research and efforts to better understand the mechanisms of disease and drug action, but also those related to general body reactance and self-healing, which are enhanced by placebo administration. Because in history ethics are swinging between two opposed views, it is possible that in the near future, the balance will move towards communitarianism, which is more likely to better serve long-term patient needs. Ethicists should also consider some other aspects of human experimentation, such as the consistency of research lines and the trend to substitute older drugs with their metabolites or enantiomers.",
keywords = "Ethics, Placebo, Randomised clinical trials",
author = "Kotzalidis, {G. D.} and I. Pacchiarotti and G. Manfredi and V. Savoja and C. Torrent and L. Mazzarini and C. Tatarelli and B. Amann and {Di Marzo}, S. and J. S{\'a}nchez-Moreno and G. Sani and P. Girardi and F. Colom and E. Vieta",
year = "2008",
month = "8",
doi = "10.1177/0269881108089576",
language = "English",
volume = "22",
pages = "590--597",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Ethical questions in human clinical psychopharmacology

T2 - Should the focus be on placebo administration?

AU - Kotzalidis, G. D.

AU - Pacchiarotti, I.

AU - Manfredi, G.

AU - Savoja, V.

AU - Torrent, C.

AU - Mazzarini, L.

AU - Tatarelli, C.

AU - Amann, B.

AU - Di Marzo, S.

AU - Sánchez-Moreno, J.

AU - Sani, G.

AU - Girardi, P.

AU - Colom, F.

AU - Vieta, E.

PY - 2008/8

Y1 - 2008/8

N2 - Of all ethical issues in clinical trial designs, only placebo use is dealt with acrimony and unwarranted, rhetoric emphasis. Many misconceptions are biased and may hamper research in the mechanisms of healing and recovery if placebo is banned from clinical trials, as some influential ethicists propose. Current treatments in psychiatry are by no means optimal and may vary in their effect across studies, rendering difficult to find the best available therapeutic method with which to compare new drugs. Because drugs possess specific mechanisms, it is not possible to compare drugs with different mechanisms as to their relevance in the pathophysiology of a given disorder. Placebo acts through non-specific mechanisms and is the ideal control for any disorder whose pathophysiology is relatively unknown and its treatment is still suboptimal. Sticking to short-term patient benefit in a trial reflects an individualistically oriented thinking in contemporary ethics and is likely to limit further research and efforts to better understand the mechanisms of disease and drug action, but also those related to general body reactance and self-healing, which are enhanced by placebo administration. Because in history ethics are swinging between two opposed views, it is possible that in the near future, the balance will move towards communitarianism, which is more likely to better serve long-term patient needs. Ethicists should also consider some other aspects of human experimentation, such as the consistency of research lines and the trend to substitute older drugs with their metabolites or enantiomers.

AB - Of all ethical issues in clinical trial designs, only placebo use is dealt with acrimony and unwarranted, rhetoric emphasis. Many misconceptions are biased and may hamper research in the mechanisms of healing and recovery if placebo is banned from clinical trials, as some influential ethicists propose. Current treatments in psychiatry are by no means optimal and may vary in their effect across studies, rendering difficult to find the best available therapeutic method with which to compare new drugs. Because drugs possess specific mechanisms, it is not possible to compare drugs with different mechanisms as to their relevance in the pathophysiology of a given disorder. Placebo acts through non-specific mechanisms and is the ideal control for any disorder whose pathophysiology is relatively unknown and its treatment is still suboptimal. Sticking to short-term patient benefit in a trial reflects an individualistically oriented thinking in contemporary ethics and is likely to limit further research and efforts to better understand the mechanisms of disease and drug action, but also those related to general body reactance and self-healing, which are enhanced by placebo administration. Because in history ethics are swinging between two opposed views, it is possible that in the near future, the balance will move towards communitarianism, which is more likely to better serve long-term patient needs. Ethicists should also consider some other aspects of human experimentation, such as the consistency of research lines and the trend to substitute older drugs with their metabolites or enantiomers.

KW - Ethics

KW - Placebo

KW - Randomised clinical trials

UR - http://www.scopus.com/inward/record.url?scp=50249163827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249163827&partnerID=8YFLogxK

U2 - 10.1177/0269881108089576

DO - 10.1177/0269881108089576

M3 - Article

C2 - 18515445

AN - SCOPUS:50249163827

VL - 22

SP - 590

EP - 597

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 6

ER -